Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

The Medicine Foundry, which is expected to create 400 jobs, will be situated in the LEAP Research and Innovation District in ...

“Its patent will expire next year, and it will be available as a generic and I will introduce it to the entire public health ...

Ken Paxton accuses the three big insulin manufacturers of conspiring with the three largest pharmacy companies to overcharge patients hundreds of dollars per dose while raking in sizable profits.

(Reuters) - The Texas attorney general has sued leading insulin manufacturers and pharmacy benefit managers (PBMs), accusing ...

The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...

Novo Nordisk and Eli Lilly, whose obesity drugs are some of the most in-demand drugs in the US, have drafted plans to avoid ...

Novo Nordisk A/S Sponsored ADR Class B (NVO) is currently at $115.65, down $0.83 or 0.71% --Would be lowest close since Feb. 2, 2024, when it closed at $113.70 --Currently down six consecutive days; ...

Investors in healthcare and biotech stocks suffered over recent years but with companies like Eli Lily and Novo Nordisk ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

Eli Lilly and Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, ...

Removal of Lilly’s in-demand drugs from the FDA’s shortage list ramps up pressure on the companies selling compounded ...